Lunit to Present 21 Latest Research Findings at European Congress of Radiology 2026

Lunit, a medical artificial intelligence (AI) company, announced on March 5 that it will present 21 of its latest research findings at the "European Congress of Radiology 2026 (ECR 2026)," which will be held in Vienna, Austria, from March 4 to 8 (local time).

During this event, research evaluating the clinical value of Lunit's AI mammography analysis solution "Lunit INSIGHT MMG," breast density quantification solution "Scorecard," and chest X-ray AI analysis solution "Lunit INSIGHT CXR" will be presented. Of the 21 accepted research abstracts, 13 will be delivered as oral presentations and 8 as poster presentations.

원본보기 아이콘

One of the key studies by Lunit to be unveiled at ECR 2026 is a breast cancer early risk assessment project led by Dr. Claudia Weiss and her team at the Italian regional health authority AULSS n.2 'Marca Trevigiana' in Treviso. The researchers analyzed mammography data from 67,686 women to determine whether the risk score (ExRS) calculated using Lunit INSIGHT MMG could identify women who, despite having a negative result at their first screening, are at relatively higher risk of being diagnosed with breast cancer later on.

A study highlighting the potential for AI application in interval cancer detection will also be presented. Professor Yan Chen and her research team at the University of Nottingham in the UK evaluated the potential use of AI in the interval cancer classification process of the National Health Service Breast Screening Programme (NHSBSP) in the UK.

The results of a large-scale randomized controlled trial (RCT) using the breast density quantification solution "Scorecard" from Lunit International (formerly Volpara) will also be released. Dr. Carla van Hilst and her team at University Medical Center Utrecht in the Netherlands tracked whether supplementary MRI screening for women who had negative mammography results but were classified as having extremely dense breasts using Scorecard could reduce the incidence of advanced breast cancer.

Seokbeom Seo, CEO of Lunit, stated, "These studies demonstrate that AI can go beyond simple reading assistance to contribute to early risk assessment, quality control in screening, and the identification of high-risk groups. We will continue to build clinical evidence for global screening practices through collaboration with leading medical institutions worldwide."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.